Leonard Reyno sold $22k of CCCC
Chief Medical Officer at C4 Therapeutics, Inc.. 10,000 shares at an average of $2.22, traded Jan 16, 2026, filed Jan 16, 2026.
Score components
- +15RoleOfficer
- 0Trade size$22k at market
- 0Share of holdings soldSold 6.0% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -15.2%, 3m +30.9%, 6m +65.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001470831-26-000045, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 16, 2026 | SOpen-market sale Common Stock | -10,000 | $2.22 | $22k | 156,382 | Jan 16, 2026 |
Related signals
Other insiders at C4 Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | C4 Therapeutics, Inc. | Scott N Boyle Chief Business Officer | $3,651 1,159 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.